Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — Q2 2026 Earnings Presentation
14 slides from Zealand Pharma A/s's earnings presentation, Aug 13, 2026
Slide 1: Q2 2026 Presentation
Q2 2026 Presentation Zealand Pharma August 13, 2026
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Phar
Slide 3: Agenda
Agenda Q&A Opening remarks R&D pipeline Financials Adam Steensberg David Kendall Henriette Wennicke Chief Executive Chief Medical Chief Financial Officer Officer Officer 3
Slide 4: Significant advancements delivered since start of 2026
Opening remarks Significant advancements delivered since start of 2026 Petrelintide Early pipeline ✓ Positive ZUPREME-1 results, demonstrating ✓ Positive Phase 1a SAD topline results with Kv1.3 double-digit weight loss and tolerability profile inhibitor (ZP9830) comparable to placebo ✓ Initiated Pha
Slide 5: Tolerability, treatment persistence, and patient experience were front and center at ADA 2026
Opening remarks Tolerability, treatment persistence, and patient experience were front and center at ADA 2026 Amylin was positioned as a potential preferred first-line therapy A hypothetical treatment program for chronic weight management was proposed at ADA Complications ameliorated by High BMI Pat
Slide 6: Clinical pipeline: Five launches by 2030
R&D pipeline Clinical pipeline: Five launches by 2030 INDICATION PRODUCT CANDIDATE a PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATION Petrelintideb Obesity +/- T2D amylin analog 2026 Petrelintide/enicepatideb Obesity +/- T2D 2026 amylin/GLP-1/GIP Survodutidec Obesity +/- T2D GCGR/GLP-1R dual agonis
Slide 7: Phase 2 ZUPREME-1 results support potential of petrelintide as future first-choice therapy
R&D pipeline Phase 2 ZUPREME-1 results support potential of petrelintide as future first-choice therapy Phase 3 on track for initiation in 2026 Double-digit weight loss with no apparent plateau Tolerability profile largely comparable to placebo Baseline characteristics: 53% female, mean BMI of 37 kg
Slide 8: Expanding our petrelintide franchise with initiation of ZYNERGY trial
R&D pipeline Expanding our petrelintide franchise with initiation of petrelintide/enicepatide Phase 2 ZYNERGY trial Screening Treatment SFU petrelintide dosing regimen A Primary endpoint: enicepatide dosing regimen 1 • Percentage change in body weight from baseline to week 40 Eligibility criteria pe
Slide 9: In Phase 3 trials, survodutide demonstrated targeted visceral and liver fat reductions
R&D pipeline In Phase 3 trials, survodutide demonstrated targeted visceral and liver fat reductions SYNCHRONIZETM-11 SYNCHRONIZETM-MASLD2 • Up to 16.6% mean weight loss at Week 76 (vs. 3.2% with placebo) • 61% of participants treated with survodutide 6.0 mg reached liver at Week 76, predominantly dr
Slide 10: ZP9830 entered Phase 1b trial in participants with plaque psoriasis
R&D pipeline ZP9830 entered Phase 1b trial in participants with plaque psoriasis Data from Phase 1 MAD part expected in H2 2026 PIPELINE-IN-A-PRODUCT POTENTIAL PHASE 1B TRIAL — NEWLY INITIATED PK/PD profile in Phase 1 SAD consistent with Evaluating the safety, tolerability, PK, PD and clinical expec
Slide 11: Strong balance sheet enabling investments into future growth opportunities
Financials Strong balance sheet enabling investments into future growth opportunities 16000 Executing on key strategic priorities and more 15,109 -1,064 14,457 52 14000 -438 798 1. Maximize the value of petrelintide ✓ Initiating Phase 3 with monotherapy and Phase 2 Cash position (DKK million)a 12000
Slide 12: Net result in H1 2026 was DKK 3.5 billion driven by the Roche collaboration
Financials Net result in H1 2026 was DKK 3.5 billion driven by the Roche collaboration DKK million H1 2026 H1 2025 P&L reflecting strategic investments in differentiated R&D assets and organization Revenue 4,525 9,096 Gross profit 4,525 9,095 H1 2026 OPEX compositiona DKK million Research and develo
Slide 13: 2026 financial outlook unchanged
Financials 2026 financial outlook unchanged DKK billion 2026 Guidance 2025 Actuals Collaboration revenue 4.5 9.2 Operating expenses excl. OOIa 2.7–3.3 2.1 Royalty purchase and sale agreement with Royalty Pharma for rusfertide: • USD 100 million royalty monetization for the sale of economic interests
Slide 14: Significant pipeline progress and several Phase 2/3 clinical readouts remaining in 2026
Closing remarks Significant pipeline progress and several Phase 2/3 clinical readouts remaining in 2026 NON-EXHAUSTIVE Petrelintidea Survodutideb Building the pipeline (amylin analog) (GCGR/GLP-1R) of the future ✓ Results from Ph2 ZUPREME-1 Results from Ph3 obesity trials ZP9830 (Kv1.3) Results from